Aaron Cowen’s Heron Therapeutics HRTX Stock Holding History

Aaron Cowen’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-53,000	Closed	-$622K	–	92
2020 Q1	$622K	Buy	+53,000	New	+$996K	0.02%	58

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Aaron Cowen's HRTX Position: Q4 2022 in Review

Aaron Cowen sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 2,807,000 shares — an estimated $11.8M sold.

Aaron Cowen first reported a position in HRTX in Q1 2020 and held it in 8 quarters. The position peaked at $23.1M in Q2 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Aaron Cowen reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Aaron Cowen sold 2,807,000 Heron Therapeutics shares in Q4 2022, an estimated $11.8M.
Aaron Cowen first reported a position in Heron Therapeutics in Q1 2020 and held it in 8 quarters.
Aaron Cowen's Heron Therapeutics position peaked at $23.1M in Q2 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.